Last week, GlaxoSmithKline and Northwestern University filed separate lawsuits against Moderna, accusing its mRNA-based vaccines of ...
On Thursday, GSK plc (NYSE:GSK) revealed new preliminary data for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) in ...
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...
Right now, the only RSV vaccine pregnant people can get is the Pfizer vaccine. But there are other vaccines you can get for ...
Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.
GlobalData on MSN1d
FDA expands Pfizer’s RSV vaccine label to include all high-risk adultsAbrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...
Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals ...
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...
The FDA approved Pfizer's Abrysvo, the first and only RSV vaccine for adults aged 18 to 59 who are at increased risk of severe respiratory illness caused by RSV.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback